An article published in the journal “Nature” describes the application of neural networks to gravitational lensing. A team of researchers reduced from a few weeks to a few seconds the time needed to analyze complex space distortions in images captured thanks to gravitational lenses. This could greatly facilitate this type of task with great benefits for astronomical research.
During this week a new launch of the augmented reality glasses originally called Google Glass. Announced for the first time in April 2012, after a test phase they seemed to be one of the biggest flops in the field of technology. The new version, however, is called the Glass Enterprise Edition, in fact it’s a business product that can be useful in environments where information is sought while your hands are busy without interrupting your work can be a big help.
An article published in the journal “Nature” describes the creation of a new architecture for next-generation computers. A Stanford University and MIT team led by Max Shulaker, assistant professor at MIT, used experimental technologies such as carbon nanotubes and RRAM to create a prototype of a 3D chip that combines current computers’ CPU and RAM much faster in processing data and at the same time with a much lower power consumption.
The Japanese telecommunications holding company SoftBank Group Corp. has announced that it has reached an agreement with Alphabet Inc., the holding company Google is part of, to buy the robots producers Boston Dynamics and Schaft for a figure that hasn’t been disclosed. Google bought the two companies in December 2013 as part of a series of acquisitions in the field of robotics and artificial intelligence but something didn’t go well in its plans, which have been modified.
The ASCO 2017, the annual Meeting of the American Society of Clinical Oncology (ASCO), new data were presented regarding the experimentation of Watson for Oncology, the version of IBM’s cognitive computing system trained to recognize the symptoms of various forms of cancer and suggest a therapy. Developed within the Watson Health business unit, it showed a level of agreement with human doctors that reached 96% in cases of lung cancer.